Tung, N., Zhao, F., DeMichele, A., Prat, A., Winer, E. P., Wright, J. L., Recht, A., Weiss, A. C., Tjoe, J. A., Feldman, S. M., Rocque, G. B., Smith, M. L., O'Sullivan, C. C., Sardesai, S. D., Tang, S., Modi, S., Irvin, W. J., Unni, N., Battelli, C., Bagegni, N., Krie, A. K., George, M. A., Telli, M. L., Borges, V. F., D'Abreo, N., Shah, P., Villagrasa, P., Badve, S., Partridge, A. H., Miller, K. D., Carey, L. A., Wolff, A. C. (2026). Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02255